China Universal Asset Management Company’s Nurix Therapeutics NRIX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$399K Sell
16,457
-1,793
-10% -$30.5K 0.02% 283
2026
Q1
$283K Buy
18,250
+1,732
+10% +$28.7K 0.02% 322
2025
Q4
$313K Buy
16,518
+3,118
+23% +$44.8K 0.02% 299
2025
Q3
$124K Sell
13,400
-1,912
-12% -$19.9K 0.01% 371
2025
Q2
$174K Buy
15,312
+90
+0.6% +$973 0.02% 322
2025
Q1
$181K Buy
15,222
+202
+1% +$3.38K 0.02% 320
2024
Q4
$283K Buy
15,020
+2,632
+21% +$60.3K 0.03% 300
2024
Q3
$278K Buy
12,388
+5,419
+78% +$123K 0.03% 275
2024
Q2
$145K Sell
6,969
-2,435
-26% -$37.9K 0.02% 272
2024
Q1
$138K Buy
9,404
+3,793
+68% +$40.8K 0.02% 338
2023
Q4
$57.9K Buy
5,611
+4,367
+351% +$29.9K 0.01% 355
2023
Q3
$9.78K Buy
1,244
+622
+100% +$5.68K ﹤0.01% 347
2023
Q2
$6.21K Sell
622
-19
-3% -$194 ﹤0.01% 349
2023
Q1
$5.69K Buy
641
+162
+34% +$1.69K ﹤0.01% 352
2022
Q4
$5.26K Buy
479
+39
+9% +$470 ﹤0.01% 292
2022
Q3
$6K Buy
+440
New +$6.96K ﹤0.01% 260

Other funds holding NRIX

China Universal Asset Management Company's NRIX Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Nurix Therapeutics (NRIX) stake by 9.8% in Q2 2026, selling an estimated $30.5K and leaving 16,457 shares worth $399K. The position accounts for 0.02% of the portfolio, ranked #283.

China Universal Asset Management Company first reported a position in NRIX in Q3 2022 and has held it in 16 quarters since. 25 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • China Universal Asset Management Company held 16,457 shares of Nurix Therapeutics worth $399K as of Q2 2026.
  • China Universal Asset Management Company sold 1,793 Nurix Therapeutics shares in Q2 2026, an estimated $30.5K.
  • Nurix Therapeutics made up 0.02% of China Universal Asset Management Company's portfolio in Q2 2026, its #283 holding.
  • China Universal Asset Management Company first reported a position in Nurix Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • 25 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.